Contact this trialFirst, we need to learn more about you.
HIF-2 Alpha Inhibitor
Belzutifan + Palbociclib for Kidney Cancer
Recruiting1 awardPhase 1 & 2
Chicago, Illinois
This trial is testing belzutifan alone and with palbociclib in patients with advanced kidney cancer who haven't responded to other treatments. Belzutifan helps starve cancer cells of oxygen, and palbociclib stops them from growing. Belzutifan (Welireg™) is an oral small molecule inhibitor of hypoxia-inducible factor (HIF)-2α, first approved in the USA for treating patients with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC).
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service